MLKL and colonic neoplasm: Pretreatment with the RIPK1 inhibitors necrostatin-1 or necrostatin-1s or the MLKL inhibitor necrosulfonamide prevented phosphorylation of RIPK1 after DC661 (1 μM) treatment in melanoma cells (Figure 2G) but failed to rescue DC661-induced cytotoxicity in melanoma cells (Figure 2H) or colon cancer or pancreatic cancer cells (Supplemental Figure 2G).